EPIAXIS EXPANDS ITS PHASE 1 METASTATIC BREAST CANCER TRIAL

EpiAxis Therapeutics, a University of Canberra spin out company, has expanded its clinical trial program to include two additional recruitment centres for its Phase 1b metastatic breast cancer program.  Those centres are open for patient recruitment at the Southern...

read more

 

Professor Sudha Rao